Senti Biosciences (SNTI) has issued an update.
Senti Biosciences, Inc. announced significant leadership changes with Dr. Timothy Lu stepping down as President while continuing as CEO. Dr. Kanya Rajangam, formerly Head of R&D and Chief Medical Officer, has been appointed as the new President from May 14, 2024. Dr. Rajangam brings a wealth of experience from previous roles in various biopharmaceutical companies and holds a medical degree and Ph.D. in biomedical engineering. Her employment terms include a competitive salary, bonus potential, stock options, and severance benefits, enhancing the company’s executive strength amid its strategic evolution.
See more insights into SNTI stock on TipRanks’ Stock Analysis page.
